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Photodynamic therapy (PDT) has been introduced in the early eighties for treating patients
with malignancies in the tracheobronchial tract. After intravenous injection of the
photosensitizers, the tumor area in the tracheobronchial tree is illuminated bronchoscopically
using a laser fiber to transmit light of a specific wavelength during the procedure. Secondary
tissue necrosis ensues, because ofthe thrombosis ofthe tumor vasculature leading to late tissue
hypoxia. Ample data have shown thatPDT is effective to obtain full depth tissue necrosis with
relative sparing of the normal tissue. Local tumor control can be achieved. Competitive
endoscopic techniques such as lasers and electrocautery are applicable to debulk tumor in a
less selective but more immediate manner. Skin photosensitivity is a potential morbidity of
PDT, especially in using the first generation photosensitizers. This limits its palliative
potential. More selective and more phototoxic sensitizers in combination with the use of
portable diode laser, may improve the clinical usefulness of PDT in the management of
lung cancer patients. However, cost-effectiveness studies comparing PDT and other local
bronchoscopic treatment modalities such as thermal lasers, electrocautery, cryotherapy,
brachytherapy, whether or not in addition to external radiotherapy and chemotherapy, should
be conducted to define its definite role in the palliative treatment of advanced obstructive
bronchial cancers.
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INTRODUCTION
Lung cancer is a disease ofepidemic proportion and
is the global cause of cancer death. Only a minority
of the patients, about 13%, will be cured. Palliation
is an important part ofthe lung cancer management
due to the late stage of disease at presentation,
and the high rate of recurrent and metastatic dis-
ease despite previous conventional treatments.
Advanced local disease in the central airways has
morbid implications [1-5]. About 30-40% of all
lung cancer patients with locally advanced disease is
estimated to suffer from tumor obstruction inwhom
external radiotherapy is considered the treatment of
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choice for local control. This category of patients
may also be candidates for bronchoscopic treat-
ment. Tumor obstruction causes various pulmon-
ary symptoms: dyspnea, hemoptysis, stridor, and
obstructive pneumonia. Ultimately, severe impair-
ment of the gas exchange will lead to respiratory
failure. Efforts should be undertaken to improve the
quality of life despite the poor prognosis of many
patients with advanced stage cancer. Bronchoscopic
treatment modalities may provide symptomatic
relief, enabling the bronchoscopist to perform
tumor debulking [6]. Stent insertion is also possible
in cases with extraluminal compression of the
airway [7]. These intervention techniques have been
shown to be feasible and effective, however, some
limitations exist. Experience, skill and knowledge of
the anatomy is important to prevent serious
complications such as fistula and fatal hemorrhage.
It is more difficult to treat tumor extending distal
to the segmental bronchi beyond the visibility of
the bronchoscopist. The depth of tumor necrosis
depends not only on the treatment modality but also
on technical performance. The bronchoscopist has
to understand the anatomy of the tracheobronchial
wall to prevent complications. The tracheobron-
chial tree is anatomically close to vital organs,
especially pulmonary vessels accompanying its
branches. This short review will deal with the role
of photodynamic therapy in treating patients with
locally advanced lung cancer.
TECHNICAL CONSIDERATIONS
Photodynamic therapy (PDT) is the combined use
of light and photosensitizers in the presence of
oxygen to obtain tissue necrosis. Many reviews have
dealt with the basic issues and mechanisms ofPDT
[8-11]. In treating lung cancer, patients are given
sensitizers systemically by intravenous route [8,11].
The drugs used for PDT in lung cancer were mainly
hematoporphyrin derivative (HpD) and its puri-
fied product di-hematoporphyrin ether (Porfimer
Sodium, Photofrin IIR, QLT Vancouver Canada),
developed by Dougherty [8]. Advised drug doses are
2-5 and 1-2mg/kg respectively. After 24-48h,
sufficient sensitizers molecules are accumulated in
tumor tissue. No significant drug toxicity has been
reported, except for the skin photosensitivity for 6
weeks or more post-injection [12]. The drug will
gradually be metabolized and photobleached. Skin
phototoxicity such as skin redness and edema, has
been reported to occur in 20-40% of the patients
without causing any irreversible skin scarring.
More recent reports have used other more
phototoxic sensitizers which interact with light of
another wavelength [13]. This may optimize treat-
ment efficacy in two ways: lower dose sensitizers
may significantly reduce skin photosensitivity,
while necrosis in depth is obtainable due to the
deeper penetration of light with a longer wave-
length. It has been argued that selective tumor
damage is attributable to the selective illumination,
rather than tissues’ selective retention of photo-
sensitizer molecules. Nevertheless, full regeneration
ofnormal tissue after PDT has been shown and the
fact that PDT does not damage the bronchial
cartilage may prove to be advantageous in clinical
practice [14]. In vivo studies have shown that the
main effect of PDT is acute vascular thrombosis
(vascular shut-off), leading to secondary hypoxia
and late necrosis [15]. Complex issues remain to be
investigated such as the drug pharmacokinetics, the
optimal time gate between drug injection and
illumination, the sensitizers degradation and deple-
tion of oxygen during illumination procedure
[8-11,16]. Tumor illumination is easy to perform.
Many laser fibers are commercially available to
assure homogeneous light distribution. The flexible
laser fibers allow easy manipulation for treating
tumor extending into the segmental bronchi. The
thin laser fiber can be passed through the working
channel of a fiberoptic bronchoscope [8,11]. It is
better to illuminate a larger area than the suspicious
lesion alone because tumor margins are difficult to
delineate. Interstitial illumination are mostly used
by sticking the cylindrical diffusers in the intra-
luminal tumor mass, enabling sideways and more
homogeneous illumination along the tracheobron-
chial wall. Currently, cheaper and more practicalPDT FOR ADVANCED LUNG CANCER 247
diode lasers are available as light sources (see Fig. 1),
which greatly improved the process of illumination
compared to the previous bulky, more expensive
and difficult to maintain dye laser equipments. The
wavelength of light has to correlate with the
absorbance characteristics of each sensitizers, to
achieve optimal penetration of light photons in
tissue [8,17]. This is why forHpD and DHE, light of
630nm wavelength is used. Another interesting
approach is the deliberate use of a specific wave-
length, to obtain either superficial or in depth
necrosis, to match the tumor thickness preventing
overtreatment which may lead to cicatritial fibrosis
or perforation [18]. This is particularly important in
treating hollow organs to reduce the chance of
perforation and extensive tissue scarring. Limiting
the damage of normal parenchyma in preserving
lung function is the goal of selective treatment in
patients whose lung capacity is already reduced by
COPD, recurrent tumor, surgical resection and
radiotherapy. Light dosimetry remains one of the
complex issues inPDT [8,11,16]. The ultimate tissue
necrosis depends on the activation of sensitizers by
light photons in the presence of oxygen. The ideal
situation will be the predictability of light dose and
light dose fractionation to achieve optimal necrosis
in each individual patient at each particular PDT
session, taking into account the individual variabil-
ity of drug molecules distribution. Tumor mass in
each individual case is also different in shape and
size. Tracheobronchial wall is also non-homoge-
neous in structure. Photons distribution, absorp-
tion, scattering and reflection in tumor tissue
containing sensitizers molecules are complex vari-
ables. It remains to be seen, whether a feedback
monitoring during the illumination process using
the real time fluorescence measurement is clinically
practical to optimize tumor damage [18].
Standard protocol of illumination currently
applied is in the range of 100-200 J per cm tumor
FIGURE A diode laser is now available for light illumination during PDT. After patients have been given photosensitizers,
the lesion is illuminated using special laser fiber which transmits the light homogenously around or in the tumor area.248 T.G. SUTEDJA
length axis [8,11]. Bronchoscopic PDT for tumor
obstruction in the large airways does not allow long
duration of illumination due to the poor condition
of many patients. Treatment modalities such as
PDT, especially when performed under local
anesthesia have to be limited to 15-20min to
minimize the risk of respiratory failure. Secondary
necrosis and formation of fibrin plugs require
prompt action for a "clean-up" bronchoscopy to
remove debris. If necessary, re-illumination may
be performed. Afterwards, further considerations
should be made whether patients should receive
additional palliative treatment [6].
PATIENTS SELECTION
Respiratory failure may already be imminent if
there is a significanttumor obstruction ofthe central
airways. Bulky peribronchial disease cannot be
treated solely by any debulking technique. Reopen-
ing the airway lumen does not always result in the
improvement ofgas exchange ifthere is a significant
reduction of local perfusion due to tumor infiltra-
tion in thepulmonary circulation. Also patientswho
had received external irradiation may obtain less
benefit. So, careful consideration has to be made in
considering PDT as the treatment of choice [19,20].
The late secondary necrosis of PDT makes it
unsuitable for patients with severe tracheal obstruc-
tion. Immediate airway clearance using techniques
such as electrocautery or lasers in combination with
mechanical tumor removal are better alternatives.
After tumor illumination during PDT, a clean-up
bronchoscopy is essential and may be promptly
required for removal of fibrin plugs and necrosis to
prevent respiratory failure [8,11]. Light penetra-
tion is also finite. Moreover, one has to consider
treatment morbidity in case of palliation. Skin
photosensitivity may well be less burdensome for
the individual patient, however, there are several
alternatives for immediate and non-immediate
tumor debulking in case of tumor obstruction in
the tracheobronchial tree [6].
Thermal lasers such as Nd-YAG laser and
electrocautery can obtain a more immediate effect
in a less selective way. Cryotherapy is a cheaper
technique also causing secondary effect and is
equally safe for bronchial cartilage [21]. High dose
rate brachytherapy is technically a sophisticated
method of intraluminal irradiation with short
treatment time, but damage to normal tissue may
lead to radiation bronchitis, scarring and fistula
[22]. It is therefore important to compare the cost
effectiveness of PDT and other bronchoscopic
techniques in patients with advanced lung cancer.
Many patients with advanced lung cancer will
succumb from metastatic disease. PDT and other
treatment modalities may provide long duration of
local control, while sparing normal lung paren-
chyma as much as feasible. Local control and
distant control are not independent factors in lung
cancer care [23]. There is virtually no improvement
of quality of life when neither local nor distant
control can be achieved. Both local and distant
tumor controls are equally important. Long dura-
tion of symptomatic relief does improve quality of
life of patients suffering from end-stage cancer.
Looking for new avenues for the optimal applica-
tion of therapeutic modalities to provide long term
benefit and improve the chance for cure iswarranted
[24,25].
The various bronchoscopic treatment modalites
in this category ofpatients share the similarproblem
of a negative selection bias [19]. Many patients are
suffering from recurrences after previous treat-
ments. They are mostly limited in their pulmonary
and cardiac functions because of smoking history,
underlying diseases such asCOPD, previous surgery
and external radiation therapy [3,6,19]. So, inade-
quate performance of intervention techniques can
worsen patients’ condition if significant residual
tumor obstruction in the major airways persists.
PDT illumination, however, is easy to perform. One
has only to position the fiber on top of (surface
illumination), or in the tumor area (interstitial
illumination). The aiming of the laser fiber is much
less risky and requires less manipulation than Nd-
YAG laser or electrocautery. Secondary necrosis
requires clean-up bronchoscopy for removal of
tissue debris and fibrin plugs. The bronchoscopist
has to avoid respiratory failure and may use thePDT FOR ADVANCED LUNG CANCER 249
opportunity to re-illuminate the tumor. Patients
have to be protected from UV light (sunlight) after
sensitizers have been injected. Photosensitizers are
retained in the skin for a period of 6 weeks or more,
and only gradually being metabolized and photo-
bleached [8,11,12].
PDT may provide an option to reduce intralum-
inal tumor extent enabling a less extensive surgical
resection afterwards [24]. PDT and other broncho-
scopic treatment modalities should be part of the
treatment strategy within the framework of lung
cancer care in combination with surgery, chemo-
therapy and radiotherapy. This multidisciplinary
approach focuses on both palliation and treatment
with curative intent [6,8,11,20,24,25].
CLINICAL RESULTS
rhages were reported after PDT and might be
related to the negative selection bias of patients’
population. Bulky tumor might have infiltrated the
big vessels around the tracheobronchial tree prior to
treatment. Tumor recurrences after conventional
treatments such as surgery and external radio-
therapy are often the tip of an iceberg. New data
slowly emerge in using more phototoxic photo-
sensitizers such as m-THPC in treating early lung
cancers [18]. The availability ofportable diode laser
in compact format (see photograph) makes PDT
more practical to perform, but more phase III
studies are needed to compare the cost-effectiveness
of various palliative bronchoscopic treatments.
Whether the use of the new generation sensitizers
in combination with the diode laser may become
more popular for palliation andbecome competitive
to other techniques, remains to be seen.
Several PDT phase II and phase III studies have
been published [26-33]. In general, they all showed
that recanalization ofthe tracheobronchial tree can
be achieved, irrespective of the previous treatments
given to the patients. One has to remember that
locally advanced cancer is by no means a homo-
geneous disease and that response parameters have
been used in different ways in reporting results.
Nevertheless, PDT has been shown to be effective
for intraluminal tumor debulking and in achieving
long term local control (see Table I). Skin photo-
senstitivity is the only potential morbidity. Hemor-
FUTURE PROSPECTS
Ample data have shown the clinical efficacy ofPDT
for the treatment oflung cancer, also in patientswith
extensive local disease [26-33]. Despite its complex
mechanisms and the use ofbulky laser equipment in
the past, many studies have also confirmed its
efficacy and established the role ofPDT in treating
superficial early stage lung cancer [11,20,24,25,34].
The issue is thus more controversial in usingPDT
for treating patients with locally advanced cancers
TABLE Response of palliation with PDT in patients’ subgroups with advanced stage and obstruc-
tive lung tumors
References [no.] n Response Survival (months)
Hayata [26] 14
Balchum [27] 81
Vincent [28] 17
Li [29] 21
Edell [30] 38
Sutedja [31] 26
Randomized studies
Lam [32] RT alone vs 22
PDT+ RT
Moghissi [33] 26
PDT vs Nd-YAG
63% Up to <16
99% Median <7
76% Median 1.5
83% Not available
68% 3-53
73% Median 4
PDT+ RT gave
longer remission
PDT: better response and
lung function improvement
Abbreviations: n number of patients in the study; RT radiotherapy.
4-10
Not available250 T.G. SUTEDJA
[6,7,19,20,35]. The secondary mechanism of tumor
necrosis, the availability of other treatment mod-
alities that can be applied for immediate palliation
and the cost-effectiveness issue are factors to be
considered before choosingPDT for palliation. Less
skin phototoxic second generation sensitizers and
the availabilty ofportable diode lasers can certainly
improve PDT application. Many centers perform-
ingPDT also have Nd-YAG laser or electrocautery
facilities. As immediate results can be obtained and
concurrent placement ofa stent ismade possible, the
preference for these alternative techniques are obvi-
ous. PDT achieves secondary or non-immediate
necrosis and is therefore comparable to techniques
such as high dose rate brachytherapy and cryother-
apy [6]. The choice oftreatment is also based on the
patients’ population referred to each particular
institution.
In summary, it remains to be seen whether PDT
using new photosensitizers in combination with
diode lasers may provide a cost-effective alternative
for bronchoscopic treatment in patients with locally
advanced lung cancer.
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